Amneal Pharmaceuticals announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, a New York-based pharmaceutical manufacturer of prescription tablet and capsule formulations. The agreement is effective March 22, 2019. The agreement includes an upfront milestone payment upon commercialization and a profit share on future sales of Levothyroxine. Further terms of the agreement were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.